Patient-specific pluripotent stem cell-based Parkinson’s disease models showing endogenous alpha-synuclein aggregation

키워드

참고문헌 (86)

1. Olanow CW, "Etiology and pathogenesis of Parkinson's disease", Annu Rev Neurosci, 22, pp.123~144 (1999)
2. Dauer W, "Parkinson's disease : mechanisms and models", Neuron, 39, pp.889~909 (2003)
3. Polymeropoulos MH, "Mutation in the alpha-synuclein gene identified in families with Parkinson's disease", Science, 276, pp.2045~2047 (1997)
4. Singleton AB, "alpha-Synuclein locus triplication causes Parkinson's disease", Science, 302, pp.841~ (2003)
5. Chartier-Harlin MC, "Alpha-synuclein locus duplication as a cause of familial Parkinson's disease", Lancet, 364, pp.1167~1169 (2004)
6. Lee VM, "Mechanisms of Parkinson's disease linked to pathological alpha-synuclein : new targets for drug discovery", Neuron, 52, pp.33~38 (2006)
7. Fujiwara H, "alpha-Synuclein is phosphorylated in synucleinopathy lesions", Nat Cell Biol, 4, pp.160~164 (2002)
8. Jackson-Lewis V, "Animal models of Parkinson's disease", Parkinsonism Relat Disord, 18(Suppl 1), pp.S183~S185 (2012)
9. Koprich JB, "Animal models of alpha-synucleinopathy for Parkinson disease drug development", Nat Rev Neurosci, 18, pp.515~529 (2017)
10. Brennand KJ, "Modelling schizophrenia using human induced pluripotent stem cells", Nature, 473, pp.221~225 (2011)
11. Dimos JT, "Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons", Science, 321, pp.1218~1221 (2008)
12. Laflamme MA, "Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts", Nat Biotechnol, 25, pp.1015~1024 (2007)
13. Li XJ, "Specification of motoneurons from human embryonic stem cells", Nat Biotechnol, 23, pp.215~221 (2005)
14. Maroof AM, "Prospective isolation of cortical interneuron precursors from mouse embryonic stem cells", J Neurosci, 30, pp.4667~4675 (2010)
15. Cunningham M, "hPSC-derived maturing GABAergic interneurons ameliorate seizures and abnormal behavior in epileptic mice", Cell Stem Cell, 15, pp.559~573 (2014)
16. Joseph NM, "Toward an understanding of the physiological function of Mammalian stem cells", Dev Cell, 9, pp.173~183 (2005)
17. Saha K, "Technical challenges in using human induced pluripotent stem cells to model disease", Cell Stem Cell, 5, pp.584~595 (2009)
18. Li H, "Modeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells", J Parkinsons Dis, 8, pp.479~493 (2018)
19. Sison SL, "Using Patient-Derived Induced Pluripotent Stem Cells to Identify Parkinson's Disease-Relevant Phenotypes", Curr Neurol Neurosci Rep, 18, pp.84~ (2018)
20. Ueda K, "Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease", Proc Natl Acad Sci U S A, 90, pp.11282~11286 (1993)
21. Weinreb PH, "NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded", Biochemistry, 35, pp.13709~13715 (1996)
22. Davidson WS, "Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes", J Biol Chem, 273, pp.9443~9449 (1998)
23. Bartels T, "alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation", Nature, 477, pp.107~110 (2011)
24. Wang W, "A soluble alpha-synuclein construct forms a dynamic tetramer", Proc Natl Acad Sci U S A, 108, pp.17797~17802 (2011)
25. Dettmer U, "Parkinsoncausing alpha-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation", Nat Commun, 6, pp.7314~ (2015)
26. Tong J, "Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy : a comparative investigation", Brain, 133, pp.172~188 (2010)
27. Winklhofer KF, "The two faces of protein misfolding : gain-and loss-of-function in neurodegenerative diseases", EMBO J, 27, pp.336~349 (2008)
28. McCann H, "alpha-Synucleinopathy phenotypes", Parkinsonism Relat Disord, 20(Suppl 1), pp.S62~S67 (2014)
29. Savica R, "Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism", JAMA Neurol, 70, pp.859~866 (2013)
30. Oueslati A, "Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein : implications for Parkinson's disease pathogenesis and therapies", Prog Brain Res, 183, pp.115~145 (2010)
31. Anderson JP, "Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease", J Biol Chem, 281, pp.29739~29752 (2006)
32. Chen L, "Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease", Nat Neurosci, 8, pp.657~663 (2005)
33. Yamada M, "Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9 : resemblance to pathogenetic changes in Parkinson's disease", J Neurochem, 91, pp.451~461 (2004)
34. Takahashi M, "Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila", Neurosci Lett, 336, pp.155~158 (2003)
35. Oueslati A, "Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?", J Parkinsons Dis, 6, pp.39~51 (2016)
36. Tenreiro S, "Protein phosphorylation in neurodegeneration: friend or foe?", Front Mol Neurosci, 7, pp.42~ (2014)
37. Arenas E, "How to make a midbrain dopaminergic neuron", Development, 142, pp.1918~1936 (2015)
38. Park CH, "In vitro and in vivo analyses of human embryonic stem cell-derived dopamine neurons", J Neurochem, 92, pp.1265~1276 (2005)
39. Zeng X, "Dopaminergic differentiation of human embryonic stem cells", Stem Cells, 22, pp.925~940 (2004)
40. Perrier AL, "Derivation of midbrain dopamine neurons from human embryonic stem cells", Proc Natl Acad Sci U S A, 101, pp.12543~12548 (2004)
41. Sonntag KC, "Enhanced yield of neuroepithelial precursors and midbrain-like dopaminergic neurons from human embryonic stem cells using the bone morphogenic protein antagonist noggin", Stem Cells, 25, pp.411~418 (2007)
42. Roy NS, "Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes", Nat Med, 12, pp.1259~1268 (2006)
43. Kim BK, "Neurogenic effect of vascular endothelial growth factor during germ layer formation of human embryonic stem cells", FEBS Lett, 580, pp.5869~5874 (2006)
44. Swistowski A, "Xeno-free defined conditions for culture of human embryonic stem cells, neural stem cells and dopaminergic neurons derived from them", PLoS One, 4, pp.e6233~ (2009)
45. Chambers SM, "Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling", Nat Biotechnol, 27, pp.275~280 (2009)
46. Fasano CA, "Efficient derivation of functional floor plate tissue from human embryonic stem cells", Cell Stem Cell, 6, pp.336~347 (2010)
47. Kriks S, "Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease", Nature, 480, pp.547~551 (2011)
48. Chambers SM, "Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors", Nat Biotechnol, 30, pp.715~720 (2012)
49. Soldner F, "Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors", Cell, 136, pp.964~977 (2009)
50. Baba M, "Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies", Am J Pathol, 152, pp.879~884 (1998)
51. Mazzulli JR, "alpha-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models", Proc Natl Acad Sci U S A, 113, pp.1931~1936 (2016)
52. Giasson BI, "Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions", Science, 290, pp.985~989 (2000)
53. Lin L, "Molecular Features Underlying Neurodegeneration Identified through In Vitro Modeling of Genetically Diverse Parkinson's Disease Patients", Cell Rep, 15, pp.2411~2426 (2016)
54. Kouroupi G, "Defective synaptic connectivity and axonal neuropathology in a human iPSC-based model of familial Parkinson's disease", Proc Natl Acad Sci U S A, 114, pp.E3679~E3688 (2017)[DOI]
55. Ryan SD, "Isogenic human iPSC Parkinson's model shows nitrosative stressinduced dysfunction in MEF2-PGC1alpha transcription", Cell, 155, pp.1351~1364 (2013)
56. Mazzulli JR, "Activation of beta-Glucocerebrosidase Reduces Pathological alpha-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons", J Neurosci, 36, pp.7693~7706 (2016)
57. Prots I, "alpha-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies", Proc Natl Acad Sci U S A, 115, pp.7813~7818 (2018)
58. Ludtmann MHR, "alpha-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson's disease", Nat Commun, 9, pp.2293~ (2018)
59. Tagliafierro L, "Multiplication of the SNCA locus exacerbates neuronal nuclear aging", Hum Mol Genet, 28, pp.407~421 (2019)
60. Klein C, "Genetics of Parkinson's disease", Cold Spring Harb Perspect Med, 2, pp.a008888~ (2012)
61. di Domenico A, "Patient-Specific iPSC-Derived Astrocytes Contribute to Non-Cell-Autonomous Neurodegeneration in Parkinson's Disease", Stem Cell Reports, 12, pp.213~229 (2019)
62. Shaltouki A, "Mitochondrial alterations by PARKIN in dopaminergic neurons using PARK2 patient-specific and PARK2 knockout isogenic iPSC lines", Stem Cell Reports, 4, pp.847~859 (2015)
63. Chung SY, "Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and alpha-Synuclein Accumulation", Stem Cell Reports, 7, pp.664~677 (2016)
64. Hruska KS, "Gaucher disease : mutation and polymorphism spectrum in the glucocerebrosidase gene(GBA)", Hum Mutat, 29, pp.567~583 (2008)
65. Nalls MA, "A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies", JAMA Neurol, 70, pp.727~735 (2013)
66. Sidransky E, "Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease", N Engl J Med, 361, pp.1651~1661 (2009)
67. Eblan MJ, "The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews", N Engl J Med, 352, pp.728~731 (2005)[DOI]
68. Goker-Alpan O, "Parkinsonism among Gaucher disease carriers", J Med Genet, 41, pp.937~940 (2004)
69. Halperin A, "Increased incidence of Parkinson disease among relatives of patients with Gaucher disease", Blood Cells Mol Dis, 36, pp.426~428 (2006)
70. Lwin A, "Glucocerebrosidase mutations in subjects with parkinsonism", Mol Genet Metab, 81, pp.70~73 (2004)
71. Kim S, "GBA1 deficiency negatively affects physiological alpha-synuclein tetramers and related multimers", Proc Natl Acad Sci U S A, 115, pp.798~803 (2018)
72. Luk KC, "Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells", Proc Natl Acad Sci U S A, 106, pp.20051~20056 (2009)
73. Soria-Valles C, "iPSCs : On the Road to Reprogramming Aging", Trends Mol Med, 22, pp.713~724 (2016)
74. Zeltner N, "Pluripotent stem cell-based disease modeling : current hurdles and future promise", Curr Opin Cell Biol, 37, pp.102~110 (2015)
75. Vera E, "When rejuvenation is a problem : challenges of modeling late-onset neurodegenerative disease", Development, 142, pp.3085~3089 (2015)
76. Studer L, "Programming and Reprogramming Cellular Age in the Era of Induced Pluripotency", Cell Stem Cell, 16, pp.591~600 (2015)
77. Miller JD, "Human iPSC-based modeling of late-onset disease via progerin-induced aging", Cell Stem Cell, 13, pp.691~705 (2013)
78. Bolognin S, "3D Cultures of Parkinson's Disease-Specific Dopaminergic Neurons for High Content Phenotyping and Drug Testing", Adv Sci (Weinh), 6, pp.1800927~ (2019)
79. Jo J, "Midbrain-like Organoids from Human Pluripotent Stem Cells Contain Functional Dopaminergic and Neuromelanin-Producing Neurons", Cell Stem Cell, 19, pp.248~257 (2016)
80. Monzel AS, "Derivation of Human Midbrain-Specific Organoids from Neuroepithelial Stem Cells", Stem Cell Reports, 8, pp.1144~1154 (2017)
81. Peng J, "Synergistic effects of environmental risk factors and gene mutations in Parkinson's disease accelerate age-related neurodegeneration", J Neurochem, 115, pp.1363~1373 (2010)
82. Havlicek S, "Gene dosage-dependent rescue of HSP neurite defects in SPG4patients' neurons", Hum Mol Genet, 23, pp.2527~2541 (2014)
83. Tagliafierro L, "Genetic analysis of alpha-synuclein 3' untranslated region and its corresponding microRNAs in relation to Parkinson's disease compared to dementia with Lewy bodies", Alzheimers Dement, 13, pp.1237~1250 (2017)
84. Hu Y, "Directed differentiation of basal forebrain cholinergic neurons from human pluripotent stem cells", J Neurosci Methods, 266, pp.42~49 (2016)
85. Crompton LA, "Stepwise, non-adherent differentiation of human pluripotent stem cells to generate basal forebrain cholinergic neurons via hedgehog signaling", Stem Cell Res, 11, pp.1206~1221 (2013)
86. Serio A, "Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43proteinopathy", Proc Natl Acad Sci U S A, 110, pp.4697~4702 (2013)

관련 논문AI추천